TLDR
- Novo Nordisk launches first oral Wegovy pill for easy weight management.
- Amazon Pharmacy delivers Wegovy nationwide with insured prices from $25.
- Oral pill offers a convenient alternative to costly weekly injections.
- One Medical kiosks and telehealth expand access to personalized care.
- Wegovy pill aims to grow the obesity treatment market and reach more patients.
Novo Nordisk(NOV) shares surged to $58.81, up 2.56%, after its Wegovy oral pill became available through Amazon Pharmacy.
NOV Inc., NOV
The daily pill represents the first FDA-approved oral GLP-1 treatment for weight management. Its launch aims to expand access beyond traditional clinics and pharmacies nationwide.
The pill is available for insured customers for as low as $25 per month. Cash-paying patients can access the starting dose at $149 monthly. This pricing positions Wegovy competitively against existing injectable obesity medications.
Amazon Pharmacy delivers the pill directly to customers’ homes across all 50 states. Same-day delivery reaches nearly half of U.S. consumers. The service allows users to compare insurance and cash-pay prices for convenience.
Amazon Pharmacy Expands Access to Weight Management Solutions
Amazon Pharmacy enables patients to receive prescriptions directly from healthcare providers without visiting a physical pharmacy. Prescriptions are delivered efficiently to customers’ doors. The service integrates eligible coupons automatically at checkout for cost transparency.
The pill will soon be available at Amazon Pharmacy Kiosks within select One Medical clinics. Customers can access comprehensive care through Amazon One Medical, including personalized evaluations and ongoing support for weight management. Partnerships with companies like WeightWatchers, Wheel, and 9amHealth broaden the reach of obesity treatments.
Amazon Pharmacy was originally launched in 2020, following its acquisition of PillPack in 2018. Later, Amazon purchased One Medical in 2022 for $3.9 billion. These moves support Amazon’s strategy to enter the $4 trillion U.S. healthcare market.
Oral Pill Could Transform Obesity Treatment Landscape
Novo Nordisk’s oral pill competes with costly weekly injections from both Novo Nordisk and Eli Lilly. Analysts view the oral option as more accessible for patients afraid of injections. Availability through multiple channels, including over 70,000 pharmacies and telehealth providers, strengthens market penetration.
Cash-paying patients can also order the pill through TrumpRx, with pricing starting at $149 per month. The oral option encourages individuals who previously avoided injections to pursue obesity treatment. Experts predict that oral treatments will expand the total addressable patient population.
Eli Lilly is developing a rival obesity pill, with FDA approval expected later this year. Novo Nordisk’s move to digital channels signals a broader strategy to reach new patient segments. With Amazon Pharmacy distribution, Wegovy becomes more convenient, transparent, and widely accessible than before.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
